Craft Brew Alliance Incorporated (NASDAQ:BREW) had a decrease of 2.38% in short interest. BREW’s SI was 1.01 million shares in December as released by FINRA. Its down 2.38% from 1.03 million shares previously. With 48,600 avg volume, 21 days are for Craft Brew Alliance Incorporated (NASDAQ:BREW)’s short sellers to cover BREW’s short positions. The SI to Craft Brew Alliance Incorporated’s float is 10.65%. The stock decreased 0.51% or $0.1 during the last trading session, reaching $19.35. About 29,362 shares traded. Craft Brew Alliance, Inc. (NASDAQ:BREW) has risen 110.98% since December 1, 2016 and is uptrending. It has outperformed by 94.28% the S&P500.
Among 10 analysts covering TherapeuticsMD (AMEX:TXMD), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. TherapeuticsMD has $34 highest and $6 lowest target. $14.75’s average target is 146.24% above currents $5.99 stock price. TherapeuticsMD had 29 analyst reports since April 4, 2016 according to SRatingsIntel. As per Wednesday, November 1, the company rating was maintained by Cantor Fitzgerald. The stock of TherapeuticsMD, Inc. (NASDAQ:TXMD) has “Buy” rating given on Monday, November 7 by Guggenheim. As per Tuesday, August 29, the company rating was maintained by Oppenheimer. Deutsche Bank maintained the shares of TXMD in report on Wednesday, September 13 with “Buy” rating. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, November 13 report. The firm has “Buy” rating by Goldman Sachs given on Monday, April 4. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, September 14. The stock of TherapeuticsMD, Inc. (NASDAQ:TXMD) has “Buy” rating given on Thursday, November 9 by Noble Financial. The firm has “Buy” rating given on Thursday, August 17 by Oppenheimer. Cantor Fitzgerald maintained TherapeuticsMD, Inc. (NASDAQ:TXMD) on Wednesday, August 16 with “Buy” rating.
TherapeuticsMD, Inc. operates as a womenÂ’s health care product company. The company has market cap of $1.30 billion. The firm makes and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. It currently has negative earnings. The Company’s pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Investors sentiment decreased to 1.04 in 2017 Q2. Its down 0.07, from 1.11 in 2017Q1. It fall, as 24 investors sold TherapeuticsMD, Inc. shares while 29 reduced holdings. 12 funds opened positions while 43 raised stakes. 153.57 million shares or 4.95% less from 161.56 million shares in 2017Q1 were reported. Barclays Public Limited Company holds 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD) or 1,356 shares. 82,575 are owned by Guggenheim Capital Ltd Liability Corporation. Prudential Financial Inc accumulated 15,060 shares or 0% of the stock. Goldman Sachs Grp owns 349,801 shares. Columbus Circle holds 2.13M shares. Tiaa Cref Invest Mngmt Ltd Liability Corp owns 421,181 shares. Ameritas Inv Ptnrs reported 12,961 shares. Raymond James And Assocs reported 0% stake. 10,000 are owned by Riggs Asset Managment Incorporated. Sg Americas Secs Ltd Limited Liability Company reported 105,217 shares. Credit Suisse Ag invested in 82,722 shares. J Goldman And Lp holds 0.18% or 632,400 shares in its portfolio. Principal Finance Gru invested in 0% or 21,711 shares. State Board Of Administration Of Florida Retirement holds 74,954 shares or 0% of its portfolio. Invesco Limited holds 0% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 35,936 shares.
The stock decreased 4.92% or $0.31 during the last trading session, reaching $5.99. About 2.41M shares traded. TherapeuticsMD, Inc. (AMEX:TXMD) has declined 46.30% since December 1, 2016 and is downtrending. It has underperformed by 63.00% the S&P500.
Analysts await TherapeuticsMD, Inc. (NASDAQ:TXMD) to report earnings on February, 22. They expect $-0.10 earnings per share, up 16.67% or $0.02 from last year’s $-0.12 per share. After $-0.07 actual earnings per share reported by TherapeuticsMD, Inc. for the previous quarter, Wall Street now forecasts 42.86% negative EPS growth.
Among 6 analysts covering Craft Brew Alliance (NASDAQ:BREW), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Craft Brew Alliance had 14 analyst reports since August 6, 2015 according to SRatingsIntel. Citigroup maintained Craft Brew Alliance, Inc. (NASDAQ:BREW) rating on Friday, September 2. Citigroup has “Neutral” rating and $20 target. The company was initiated on Monday, October 2 by Susquehanna. On Friday, August 7 the stock rating was maintained by Citigroup with “Neutral”. On Thursday, November 9 the stock rating was maintained by Cowen & Co with “Buy”. The firm earned “Buy” rating on Thursday, August 3 by Cowen & Co. The company was upgraded on Thursday, August 4 by Sidoti. The stock of Craft Brew Alliance, Inc. (NASDAQ:BREW) has “Buy” rating given on Thursday, July 13 by Cowen & Co. Cowen & Co maintained it with “Buy” rating and $20.0 target in Tuesday, September 12 report. The company was maintained on Friday, August 5 by Citigroup. The firm has “Neutral” rating by Citigroup given on Monday, November 13.
Craft Brew Alliance, Inc. brews and sells craft beers and ciders under the Kona, Widmer Brothers, Redhook, Omission, and Square Mile brand names in the United States. The company has market cap of $373.39 million. It operates in two divisions, Beer Related Operations and Brewpubs Operations. It has a 716.67 P/E ratio. The firm sells its beers directly to clients in draft, cans, and bottles at restaurants, bars, and liquor stores; and in cans and bottles at supermarkets, warehouse clubs, convenience stores, and drug stores, as well as directly to clients at its brewpubs and breweries.
Investors sentiment decreased to 1.06 in Q2 2017. Its down 0.03, from 1.09 in 2017Q1. It is negative, as 9 investors sold Craft Brew Alliance, Inc. shares while 22 reduced holdings. 12 funds opened positions while 21 raised stakes. 5.89 million shares or 0.15% more from 5.88 million shares in 2017Q1 were reported. 18,700 were reported by Deutsche Bancorp Ag. Vanguard holds 0% in Craft Brew Alliance, Inc. (NASDAQ:BREW) or 385,787 shares. Bank Of Mellon Corp stated it has 0% of its portfolio in Craft Brew Alliance, Inc. (NASDAQ:BREW). Nationwide Fund Advsrs invested 0% of its portfolio in Craft Brew Alliance, Inc. (NASDAQ:BREW). Moreover, First Manhattan has 0.01% invested in Craft Brew Alliance, Inc. (NASDAQ:BREW) for 82,332 shares. Sei Invests has invested 0% in Craft Brew Alliance, Inc. (NASDAQ:BREW). Schwab Charles Inv Inc owns 16,200 shares for 0% of their portfolio. Susquehanna Group Llp, Pennsylvania-based fund reported 37,972 shares. Bridgeway Inc holds 93,240 shares. Moreover, Price T Rowe Associate Md has 0% invested in Craft Brew Alliance, Inc. (NASDAQ:BREW) for 10,335 shares. Wells Fargo Mn owns 0% invested in Craft Brew Alliance, Inc. (NASDAQ:BREW) for 47,652 shares. Ameritas Inv Prtnrs reported 855 shares. Advisory Networks Ltd Limited Liability Company accumulated 29 shares or 0% of the stock. Aqr Cap Mngmt Limited Company reported 26,085 shares. Group invested in 7,870 shares or 0% of the stock.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.